<DOC>
	<DOC>NCT01376063</DOC>
	<brief_summary>The primary purpose of this study is to assess the effect of multiple doses of FG-4592 on the plasma pharmacokinetic of rosiglitazone in healthy adult subjects.</brief_summary>
	<brief_title>Study to Investigate the Interaction Between FG-4592 and Rosiglitazone in Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Healthy adult males, 18 to 45 years Body weight â‰¥ 75 kg Good health Nonsmoker Blood pressure not greater than 140/90 mm Hg Positive for any of the following: Human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or antihepatitis C virus antibody (antiHCV Ab) Blood donation or significant blood loss within 60 days prior to Day 1 Use of prescription and over the counter medications/herbal preparations is not allowed within 14 days prior to Day 1 and through treatment phase History or presence of alcoholism or drug abuse within 2 years prior to Day 1 Consumption of alcohol within 7 days prior to Day 1 or during treatment phase Positive urine drug/alcohol testing at screening or checkin visit</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>